Cuperus Roos, Tytgat Godelieve A M, Leen René, Brites Pedro, Bras Johannes, Caron Huib N, Van Kuilenburg André B P
Laboratory Genetic Metabolic Diseases and Department of Pediatrics/Emma Children's Hospital, Academic Medical Centre, University of Amsterdam, 1100 DE Amsterdam, The Netherlands.
Int J Oncol. 2008 May;32(5):1011-9.
The efficacy and mechanism of action of fenretinide (4-HPR), a vitamin A analogue, was investigated in a panel of six neuroblastoma cell lines and multicellular tumor spheroids. The latter are three dimensional cell aggregates and as such, a model for micrometastases. In all cell lines, the production of reactive oxygen species (ROS) increased with 163-680% after 1 h of treatment with 4-HPR. In addition, a decrease of the mitochondrial membrane potential of 30-75% was observed after 4 h of incubation with 4-HPR. A 6-12-fold difference was observed between the IC50 values for cell proliferation and viability between the most sensitive (IMR32) and most resistant (NASS) cell line towards 4-HPR. Flow cytometric analysis showed an increased amount of apoptotic bodies and no cell-cycle arrest. The antioxidant Trolox completely inhibited the accumulation of 4HPR-induced ROS and prevented the 4HPR-associated cytotoxicity. In all neuroblastoma spheroids, 4-HPR induced a complete cytostasis at clinical relevant concentrations (3-10 microM). Immunohistochemical analysis of 4-HPR-treated spheroids showed a decreased staining for proliferation marker Ki-67 and an increased staining for cleaved-PARP, a marker of apoptosis. Our results suggest that 4-HPR might be a promising agent for the treatment of micrometastases and high-risk neuroblastoma.
在一组六种神经母细胞瘤细胞系和多细胞肿瘤球体中研究了视黄酸(4-HPR)这种维生素A类似物的疗效和作用机制。后者是三维细胞聚集体,因此是微转移的模型。在所有细胞系中,用4-HPR处理1小时后,活性氧(ROS)的产生增加了163 - 680%。此外,用4-HPR孵育4小时后,观察到线粒体膜电位下降了30 - 75%。在对4-HPR最敏感(IMR32)和最耐药(NASS)的细胞系之间,细胞增殖和活力的IC50值存在6 - 12倍的差异。流式细胞术分析显示凋亡小体数量增加且无细胞周期停滞。抗氧化剂Trolox完全抑制了4-HPR诱导的ROS积累,并防止了4-HPR相关的细胞毒性。在所有神经母细胞瘤球体中,4-HPR在临床相关浓度(3 - 10 microM)下诱导完全的细胞生长停滞。对4-HPR处理的球体进行免疫组织化学分析显示,增殖标志物Ki-67的染色减少,凋亡标志物裂解的PARP的染色增加。我们的结果表明,4-HPR可能是治疗微转移和高危神经母细胞瘤的一种有前景的药物。